CGTBiologicstaleNational Cancer Institute (NCI)Phase 1
Anti-cluster of differentiation 19 (CD19, Anti-cluster of differentiation 19, Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells)
Lymphoma, B-Cell; Lymphoma, Non-hodgkins · CD19
#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 94%임상시험 1상태 ACTIVE